All In Biotech

NDA 212862 · Mylan Ireland LTD

Pretomanid

Pretomanid · Oral · Antimycobacterial

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Nov 22, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Aug 14, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

44

12 Phase 3, 9 recruiting

FAERS reports

760

739 serious, 294 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 15, 2024.

Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] . Limited Population: Pretomanid Tablet is an antimycobacterial indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) that is resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of...

Mechanism: Pretomanid is a nitroimidazooxazine antimycobacterial drug [see Microbiology (12.4) ] . Mechanism of Action Pretomanid Tablet is a nitroimidazooxazine antimycobacterial drug. Pretomanid kills actively replicating M. tuberculosis by inhibiting mycolic acid biosynthesis, thereby blocking cell wall production. Under anaerobic conditions, against non-replicating bacteria, pretomanid acts as a respiratory poison following nitric oxide release. All of these activities require nitro-reduction of pretomanid within the mycobacterial cell by the deazaflavin-dependent nitroreductase, Ddn, which is...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PRETOMANID · PRETOMANID 200MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pretomanid" as an intervention, any sponsor and status, largest first.

All 44 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death126
  • anaemia84
  • neuropathy peripheral81
  • off label use68
  • nausea57
  • electrocardiogram qt prolonged53
  • decreased appetite28
  • acute kidney injury27
  • toxicity to various agents26
  • alanine aminotransferase increased23
  • aspartate aminotransferase increased22
  • hepatotoxicity22

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20152
20163
20184
201913
20209
20214
202269
2023126
2024173
2025192
2026165

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pretomanid (Pretomanid)

2024 spending

$55K

Beneficiaries

21

70 claims

Per beneficiary

$2,596

$22.77 per unit

View as table
YearSpending
2020$5,862
2021$30,315
2022$39,555
2023$55,772
2024$54,520

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 39 on PubMed

Sponsor: Mylan Ireland LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.